170 related articles for article (PubMed ID: 28645043)
1. In vitro and in vivo behavior of DNA tetrahedrons as tumor-targeting nanocarriers for doxorubicin delivery.
Kang JH; Kim KR; Lee H; Ahn DR; Ko YT
Colloids Surf B Biointerfaces; 2017 Sep; 157():424-431. PubMed ID: 28645043
[TBL] [Abstract][Full Text] [Related]
2. A Novel AS1411 Aptamer-Based Three-Way Junction Pocket DNA Nanostructure Loaded with Doxorubicin for Targeting Cancer Cells in Vitro and in Vivo.
Taghdisi SM; Danesh NM; Ramezani M; Yazdian-Robati R; Abnous K
Mol Pharm; 2018 May; 15(5):1972-1978. PubMed ID: 29669200
[TBL] [Abstract][Full Text] [Related]
3. SL2B aptamer and folic acid dual-targeting DNA nanostructures for synergic biological effect with chemotherapy to combat colorectal cancer.
Sun P; Zhang N; Tang Y; Yang Y; Chu X; Zhao Y
Int J Nanomedicine; 2017; 12():2657-2672. PubMed ID: 28435250
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic and cellular studies of doxorubicin/daunorubicin loaded by a DNA tetrahedron for diagnostic imaging, chemotherapy, and gene therapy.
Li X; Wu Y; Zhang X; Liu J; Zhang Y; Yuan L; Liu M
Int J Biol Macromol; 2023 Nov; 251():126245. PubMed ID: 37562474
[TBL] [Abstract][Full Text] [Related]
5. A dual-targeting DNA tetrahedron nanocarrier for breast cancer cell imaging and drug delivery.
Liu X; Wu L; Wang L; Jiang W
Talanta; 2018 Mar; 179():356-363. PubMed ID: 29310244
[TBL] [Abstract][Full Text] [Related]
6. Self-assembled oligopeptide nanostructures for co-delivery of drug and gene with synergistic therapeutic effect.
Wiradharma N; Tong YW; Yang YY
Biomaterials; 2009 Jun; 30(17):3100-9. PubMed ID: 19342093
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-Modified Tetrahedral DNA Nanostructures as Drug Delivery System for Cancer Targeted Therapy.
Zhao R; Bai Y; Guo Y; Feng F; Shuang S
Macromol Biosci; 2024 Apr; 24(4):e2300420. PubMed ID: 38088938
[TBL] [Abstract][Full Text] [Related]
8. Nanomicelles based on a boronate ester-linked diblock copolymer as the carrier of doxorubicin with enhanced cellular uptake.
Xu Y; Lu Y; Wang L; Lu W; Huang J; Muir B; Yu J
Colloids Surf B Biointerfaces; 2016 May; 141():318-326. PubMed ID: 26874117
[TBL] [Abstract][Full Text] [Related]
9. Novel nanostructured enoxaparin sodium-PLGA hybrid carriers overcome tumor multidrug resistance of doxorubicin hydrochloride.
Wang J; Wu L; Kou L; Xu M; Sun J; Wang Y; Fu Q; Zhang P; He Z
Int J Pharm; 2016 Nov; 513(1-2):218-226. PubMed ID: 27628785
[TBL] [Abstract][Full Text] [Related]
10. Lactose-modified DNA tile nanostructures as drug carriers.
Akkus Sut P; Tunc CU; Culha M
J Drug Target; 2016 Sep; 24(8):709-19. PubMed ID: 26805650
[TBL] [Abstract][Full Text] [Related]
11. Multifunctional aptamer-based nanoparticles for targeted drug delivery to circumvent cancer resistance.
Liu J; Wei T; Zhao J; Huang Y; Deng H; Kumar A; Wang C; Liang Z; Ma X; Liang XJ
Biomaterials; 2016 Jun; 91():44-56. PubMed ID: 26994877
[TBL] [Abstract][Full Text] [Related]
12. Which one performs better for targeted lung cancer combination therapy: pre- or post-bombesin-decorated nanostructured lipid carriers?
Du J; Li L
Drug Deliv; 2016 Jun; 23(5):1799-809. PubMed ID: 26455787
[TBL] [Abstract][Full Text] [Related]
13. Self-assembly of DNA nanostructure containing cell-specific aptamer as a precise drug delivery system for cancer therapy in non-small cell lung cancer.
Wang N; Yu C; Xu T; Yao D; Zhu L; Shen Z; Huang X
J Nanobiotechnology; 2022 Nov; 20(1):486. PubMed ID: 36403038
[TBL] [Abstract][Full Text] [Related]
14. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
He Y; Su Z; Xue L; Xu H; Zhang C
J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
[TBL] [Abstract][Full Text] [Related]
15. Folate-mediated chondroitin sulfate-Pluronic 127 nanogels as a drug carrier.
Huang SJ; Sun SL; Feng TH; Sung KH; Lui WL; Wang LF
Eur J Pharm Sci; 2009 Aug; 38(1):64-73. PubMed ID: 19540339
[TBL] [Abstract][Full Text] [Related]
16. An improved D-α-tocopherol-based nanocarrier for targeted delivery of doxorubicin with reversal of multidrug resistance.
Lu J; Zhao W; Liu H; Marquez R; Huang Y; Zhang Y; Li J; Xie W; Venkataramanan R; Xu L; Li S
J Control Release; 2014 Dec; 196():272-86. PubMed ID: 25456831
[TBL] [Abstract][Full Text] [Related]
17. Dextran-based doxorubicin nanocarriers with improved tumor penetration.
Sagnella SM; Duong H; MacMillan A; Boyer C; Whan R; McCarroll JA; Davis TP; Kavallaris M
Biomacromolecules; 2014 Jan; 15(1):262-75. PubMed ID: 24313925
[TBL] [Abstract][Full Text] [Related]
18. Targeted doxorubicin nanotherapy strongly suppressing growth of multidrug resistant tumor in mice.
Nguyen DH; Lee JS; Bae JW; Choi JH; Lee Y; Son JY; Park KD
Int J Pharm; 2015 Nov; 495(1):329-335. PubMed ID: 26325307
[TBL] [Abstract][Full Text] [Related]
19. Polymeric nanomedicine for tumor-targeted combination therapy to elicit synergistic genotoxicity against prostate cancer.
Yang Q; Yang Y; Li L; Sun W; Zhu X; Huang Y
ACS Appl Mater Interfaces; 2015 Apr; 7(12):6661-73. PubMed ID: 25775367
[TBL] [Abstract][Full Text] [Related]
20. Drug delivery by a self-assembled DNA tetrahedron for overcoming drug resistance in breast cancer cells.
Kim KR; Kim DR; Lee T; Yhee JY; Kim BS; Kwon IC; Ahn DR
Chem Commun (Camb); 2013 Mar; 49(20):2010-2. PubMed ID: 23380739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
